MetaCap

Amarin (AMRN) vs Shattuck Labs (STTK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Shattuck Labs (STTK) has outperformed Amarin (AMRN) over the past year, gaining 119.7% versus a loss of 35.5%. Over five years, STTK leads with a -52.0% price change compared with -85.5% for AMRN. Shattuck Labs is the larger company by market cap ($454.2 million vs $444.4 million), about 1.0 times the size, while Amarin is growing revenue faster (-6.5% vs -82.5%).

Amarin converts more of its revenue into profit, with a net margin of -18.2% versus -4880.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMRN-35.47%STTK+119.70%
+314%+131%-52%
Nov 21, 20251 yearNov 20, 2026
AMRN-86.45%STTK-52.55%
+20%-39%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMRN versus STTK key metrics
MetricAMRNSTTK
Share price$10.57$4.46
Market cap$444.39M$454.22M
1-day change-6.13%-1.98%
YTD return-24.28%+22.19%
1-year return-35.47%+119.70%
5-year return-85.48%-51.99%
Forward P/E10.79—
EPS (TTM)$-0.80$-0.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$213.65M$1.00M
Revenue growth (YoY)-6.55%-82.52%
Net income (latest FY)$-38.80M$-48.81M
Gross margin56.57%—
Operating margin-23.48%-5150.80%
Net margin-18.16%-4880.90%
52-week high$17.31$8.33
52-week low$10.56$1.93
Distance from 52-week high-38.94%-46.46%
Analyst consensusnonestrong_buy
Avg. price target upside+22.99%+245.29%
Average volume79.50K1.20M
Shares outstanding42.04M101.84M
Employees8040
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • STTK has outperformed AMRN by 155.2 percentage points over the past year.
  • Amarin is more profitable, keeping -18.2 cents of every revenue dollar as net income versus -4880.9 cents for Shattuck Labs.
  • Amarin grew revenue faster in its latest fiscal year (-6.55% vs -82.52%).

About Amarin

AMRN stock →

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees

About Shattuck Labs

STTK stock →

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

AMRN vs STTK FAQ

Which is bigger, Amarin or Shattuck Labs?

Shattuck Labs (STTK) is larger, with a market capitalization of $454.22M compared with $444.39M for Amarin (AMRN).

Which stock has performed better over the past year, AMRN or STTK?

STTK returned +119.70% over the past 12 months, compared with -35.47% for AMRN (price return, excluding dividends). Past performance does not predict future results.

Are Amarin and Shattuck Labs in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons